Categories
Cannabis Oils Drug Addiction Hemp Oil In the News Latest News Medical Opioid Addiction Press Releases

Earth Science Tech Finalizes Plans for Human Trials on New CBD-Based Formula Targeting Opioid Addiction Epidemic

Doral, FL, February 28, 2018 (GLOBE NEWSWIRE) – Earth Science Tech (OTC PINK: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabinoid (CBD), nutraceutical and pharmaceutical fields, as well as on R&D for certain medical devices, today announced it has finalized plans for a 9-month human trial to assess the efficacy of its treatment combining an essential mineral element and full-spectrum cannabinoid industrial hemp oil. This is expected to increase potency as opposed to the status quo in the market today, which consists solely of essential mineral element therapy (monotherapy) in treating patients with morbid substance abuse and/or dependence. These plans were originally announced in late 2017. The purpose of this trial is to develop a methodology for treating opioid addicts, preventing fatal overdoses, and relieving side-effects from withdrawals.

The new study takes advantage of two of the properties of ETST’s full-spectrum cannabinoids industrial hemp oil that have already shown great success against addiction, based on positive feedback from customers and doctors alike. The full-spectrum cannabinoids has great potential to mix with the essential mineral element, because it can support and increase the action of other drugs and medicinal substances, offering tremendous synergy. Many promising clinical studies are ongoing around the world, with cannabinoids being a key research topic for the substance abuse treatment and psychological disorders.

The 9-month human trial will study substance abuse patients who had drug prescription treatment or dietary supplement monotherapy, full-spectrum cannabinoid monotherapy, and a combination of full-spectrum cannabinoids and a dietary supplement molecule. The patient will receive this treatment sequentially. The first three months with drug prescription treatment monotherapy or dietary supplement monotherapy, the second three months with drug prescription or dietary supplement combined with full-spectrum cannabinoids, and the last 3 months with full-spectrum cannabinoids and hemp oil.  

The choice of the molecule that will be combined with the full-spectrum cannabinoids have selected after months of meticulous due diligence. The project will test the additive nature of full-spectrum cannabidnoids with two different forms of an essential mineral element, which will be revealed soon.

Should the potential synergies between the essential mineral element and cannabinoids (mainly CBD) prove successful, as the company is confident that it will, then ETST will be positioned to bring an innovative new products to the marketplace to counteract the scourge of opioid deaths that is sweeping the US. Earth Science Tech envisions and plans on producing a nutraceutical product that could be sold over the counter to help addicts resist cravings, and a cannabinoid companion for a generic drug to make the treatment more effective and reduce the danger, toxicity, and side-effects.

The Company’s CLO, Gabriel Aviles, and CEO/CSO, Dr. Michel Aube, will be supervising the project along with the medical professional advisory board team providing their resources for the human trials. The project time frame and goal is set to be completed, along with white paper studies by early 2019. This will encourage the Company to pursue clinical studies for at least two years through the remainder of 2019 and 2020, pioneering the never before attempted research studies on these two compounds combined.

ETST is currently communicating with their third-party CGMP laboratory on  mixing the anti-opioid formula for human trials, and are in talks with rehab centers interested in participating in the study to some capacity. The Company plans on sharing updates as they progress.

 

About Earth Science Tech (ETST): Earth Science Tech has among the highest quality, purity and full-spectrum high-grade hemp CBD (cannabidiol) oil on the market. Made using the superior supercritical CO2 liquid extraction, ETST’s CBD oil is 100% natural and organic. The company’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrates that ETST is the top nutritional and dietary supplement brand for high-grade hemp CBD oil.

To learn more and to buy CBD Hemp Oil, please visit: www.earthsciencetech.com

 

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (sexually transmitted infections and/or diseases). Earth Science Pharmaceutical CEO Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit: www.EarthSciencePharmaceutical.com

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech (ETST). Cannabis Therapeutics was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals, as well as other products & solutions. Cannabis Therapeutics’ mission it to help change the health care landscape by introducing its proprietary cannabis-cannabinoid-based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit: www.CannabisThera.com

About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech (ETST). KannaBidioid is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by its unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit: www.KannaBidioiDInc.com

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Dave Demarest (305) 546-7640

Earth Science Tech Nickolas S. Tabraue, P/D/COO (305) 615-2118

Categories
Drug Addiction In the News Latest News Medical Opioid Addiction Press Releases

ETST Commences Clinical Trials to Fight U.S. Opioid Epidemic

Doral, FL, Nov. 28, 2017 (GLOBE NEWSWIRE) — Earth Science Tech (OTC PINK: ETST) (“ETST” or “the Company”), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development, commences pre-launch human trials on new CBD formula to fight against the U.S. opioid epidemic under ETST’s new, recently announced advisory board team.

ETST’s current CBD oil products have shown great success against addiction, based on feedback from customers, distributors, and doctors. ETST’s recently announced board of advisors have recommended undertaking a human clinical trial with the newly developed CBD formula, given all the positive effects it has shown with current customers. Each advisory board member has agreed to provide their resources, and has had patients volunteer to come forward for study in a double-blind clinical trial of the CBD formula that ETST will provide. The first trial study will be conducted for a total of nine months, and a white paper will be issued at the conclusion of the study. The document will be published through ETST and used for patent application, if the formula is proven to be beneficial in the human trials. Pending success, the new formula would be released in 2019.

ETST’s new CBD formula is based on industrial hemp CBD oil, mixed with a well-known natural ingredient, which has been proven to help increase dopamine levels. This newly developed formula is expected to decrease cravings and the negative effects of withdrawal in addicts.

Gabriel Aviles, ETST’s Chief Sales Officer & Director states, “I’ve received extensive positive feedback on our oil and it’s a privilege to have been engaged by such amazing, passionate professionals within the field. This formula is something that I have known about and been wanting to study further for some time. Thanks to ETST and its advisory board members, I am confident that our new formula can prove to be a way to aid and relieve symptoms suffered in our current opioid epidemic. Not only will our potential patent-pending CBD formula help many addicts, it’ll give us a niche in the CBD space, alongside our other three patent pending products that we plan to launch soon.”

Dr. Michel Aube, ETST’s CEO & Chief Science Officer, adds, “I am very impressed with the formula that came from Gabriel’s idea, and look forward to seeing the results of our new study. We are currently in the process of finalizing our current CBD patents and look forward to launching in 2018. The new CBD formula currently being studied by our advisory board will keep us innovative and continue to allow us to offer specialized natural CBD based remedies. Moreover, we will push this idea further by creating an improved generic pharmaceutical drug.”

“I am honored to have such an amazing team of individuals sharing the same passion, added Nickolas S. Tabraue, President, Director, & COO of ETST. “We have worked very hard, and jumped over many hurdles, throughout 2017 to end the year very strong and positioned towards a turning point year for ETST.” “We greatly appreciate all our supportive shareholders, and I look forward to sharing many more exciting updates as we progress.”

 

About Earth Science Tech (ETST)

Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world’s best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil.

To learn more and to buy CBD Hemp Oil please visit: www.earthsciencetech.com

View ETST’s accomplishments and reports on its High-Grade CBD Hemp Oil: (here)

 

About Earth Science Pharmaceutical

Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit: www.Earthsciencepharmaceutical.com

 

About Cannabis Therapeutics

Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit: www.Cannabisthera.com

 

About KannaBidioiD

KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by it’s unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit: www.kannabidioidinc.com

 

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

 

SAFE HARBOR ACT

Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

 

Investor Relations Dave Demarest (305)-546-7640

Earth Science Tech Nickolas S. Tabraue, P/D/COO (305)-615-2118